Key facts
- It has raised $24.4M; the latest was Later Stage VC ($4.3M) in May 2024.
- Notable investors include MassChallenge, Gaingels, Everywhere Ventures, Connecticut Innovations, Launchpad Venture Group — 23 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 23 names
- ·Watchlist + deal alerts for Torigen
- ·The full record, as it builds
Funding rounds
No funding rounds for Torigen are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Torigen
Operator of an immunotherapy cancer treatment company intended to detect and treat cancer among animals. The company's experimental autologous cancer vaccine activates the immune system against specific tumor-associated antigens found on the outside surface of the tumor cells that are different from normal self-cells, enabling surgeons to detect and eliminate cancer among companion animals without having to depend on painful surgeries and chemotherapy.
- Sector
- Business Products and Services (B2B)
- HQ
- Farmington, CT, United States
- Founded
- 2013
- Employees
- 27
- Website
- torigen.com/
- Ownership
- Privately Held (backing)
Torigen doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Torigen shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Torigen in its N-PORT filings yet. We sweep new filings monthly.